Literature DB >> 21151038

Anti-VEGF (vascular endothelial growth factor) drugs in diabetic macular oedema.

J K Chhablani.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21151038      PMCID: PMC3169227          DOI: 10.1038/eye.2010.182

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  5 in total

1.  What we don't know about avastin might hurt us.

Authors:  Mark C Gillies
Journal:  Arch Ophthalmol       Date:  2006-10

Review 2.  Steroid injection in addition to macular laser grid photocoagulation in diabetic macular oedema: a systematic review.

Authors:  Daan Steijns; Diederick Duijvesz; Marja A Breedijk; Geert J M G van der Heijden
Journal:  Acta Ophthalmol       Date:  2010-03-10       Impact factor: 3.761

3.  Intravitreal bevacizumab vs intravitreal triamcinolone combined with macular laser grid for diffuse diabetic macular oedema.

Authors:  R Forte; G L Cennamo; M Finelli; E Farese; G D'Amico; G Nicoletti; G de Crecchio; G Cennamo
Journal:  Eye (Lond)       Date:  2010-03-19       Impact factor: 3.775

4.  Pharmacokinetics of intravitreal bevacizumab (Avastin).

Authors:  Sophie J Bakri; Melissa R Snyder; Joel M Reid; Jose S Pulido; Ravinder J Singh
Journal:  Ophthalmology       Date:  2007-05       Impact factor: 12.079

Review 5.  Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema.

Authors:  Mariacristina Parravano; Francesca Menchini; Gianni Virgili
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07
  5 in total
  1 in total

1.  Combination of Navigated Macular Laser Photocoagulation and Anti-VEGF Therapy: Precise Treatment for Macular Edema under Dry Retinal Conditions.

Authors:  Ernest V Boiko; Dmitrii S Maltsev
Journal:  J Ophthalmol       Date:  2017-02-20       Impact factor: 1.909

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.